Molecular Mechanisms of Combination Adjuvants (MMCA) (R01 Clinical Trial Not Allowed)
ID: 358158Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358158

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-25-006.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jan 13, 2025, 12:00 AM UTC
  4. 4
    Due Jun 10, 2025, 12:00 AM UTC
Description

The National Institutes of Health (NIH) has announced a funding opportunity titled "Molecular Mechanisms of Combination Adjuvants (MMCA) (R01 Clinical Trial Not Allowed)" aimed at supporting research into the mechanisms of action of combined vaccine adjuvants. This initiative seeks to enhance the understanding of how multiple adjuvants work together to improve immune responses, particularly for vulnerable populations such as neonates and older adults. The NIH plans to allocate approximately $2.56 million to fund 4-6 awards, with annual budget requests expected to be under $500,000, and applications are due by June 11, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-AI-25-006-Full-Announcement.html
Jan 16, 2025, 12:06 PM UTC
RFA-AI-25-006.html
Jan 16, 2025, 12:06 PM UTC
The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), has issued a funding opportunity titled "Molecular Mechanisms of Combination Adjuvants" (RFA-AI-25-006). The purpose is to support research into the mechanisms of action of combined vaccine adjuvants, which are crucial for enhancing immune responses in vaccines. This initiative aims to advance the rational design of vaccines, particularly for populations like neonates and older adults. Eligible applicants include various institutions and organizations such as higher education institutions, nonprofits, local governments, and foreign entities. Budget requests are expected to be under $500,000 annually, with NIAID planning to allocate approximately $2.56 million to fund 4-6 awards beginning in FY 2026. The application process includes specific guidelines on collaboration, data management, and adherence to NIH policies. Applications are due by June 11, 2025, with funding priorities focused on innovative research addressing significant knowledge gaps in vaccine adjuvants, further supporting public health initiatives. The initiative acknowledges the growing need for advanced adjuvant strategies to enhance vaccine efficacy and broaden immune responses.
Similar Opportunities
Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" through the R21 grant mechanism, aimed at advancing research into innate immune memory, known as trained immunity. This initiative seeks to enhance understanding of the mechanisms, biomarkers, and functional implications of trained immunity, particularly in relation to immune system development, vaccine efficacy, and various diseases, while explicitly prohibiting clinical trials. The grant provides a maximum funding amount of $275,000, with applications accepted starting May 16, 2024, and a closing date of January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" (FO No. PAR-24-112) aimed at enhancing research on innate immune memory. This initiative seeks to support studies that identify biomarkers of trained immunity, elucidate underlying molecular mechanisms, and assess the implications for immune system function, particularly in relation to vaccines, infections, and autoimmune or allergic diseases. The funding is crucial for advancing immunological research with significant public health implications, and applications are due by June 5, 2024, and October 5, 2024. Interested applicants can find more information and submit their proposals via Grants.gov, and for inquiries, they may contact NIH Grants Information at grantsinfo@nih.gov.
Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Immune System Development and Ontogeny" under the R01 Clinical Trial Optional grant program. This initiative aims to investigate the mechanisms of early immune development in children, particularly focusing on those with in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART), and includes research on maternal and paternal immune statuses, immune cell development, and environmental influences. The program is significant for advancing laboratory research and clinical trials that enhance understanding of immune maturation in neonates and children. Eligible applicants can receive up to $400,000 per year for a maximum project duration of four years, with applications opening on April 7, 2025, and closing on January 8, 2029. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This initiative encourages applicants to utilize advancements in genetics, omics methods, and synthetic biology to explore genetic, environmental, and epigenetic factors contributing to these anomalies, which affect approximately 3% of live births in the U.S. The grant allows for budgets up to $499,999 in direct costs per year, with project periods not exceeding five years, and applications are due by February 5, 2025. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "HIV Vaccine Research and Design (HIVRAD) Program," aimed at advancing research for an effective prophylactic vaccine against HIV/AIDS. This grant encourages multi-disciplinary projects that address significant scientific questions in vaccine discovery, including preclinical evaluations in non-human primate models, while explicitly prohibiting clinical trials. The NIH plans to fund 1-2 awards totaling approximately $5 million for fiscal year 2025, with applications due by March 13, 2024, and an open submission date starting February 13, 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application guidelines available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.
Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.